Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151…
Biotechnology
US, South San Francisco [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | -6.12 | -23.54 | -22.18 | |
| Graham Fair Price | 1.49 | 12.22 | 12.04 | |
| PEG | 12.89 | 0.36 | -0.32 | |
| Price/Book | -26.66 | 2.11 | 2.88 | |
| Price/Cash Flow | 9.77 | -26.53 | -29.41 | |
| Prices/Earnings | -21.51 | -7.54 | -6.21 | |
| Price/Sales | inf | 0.00 | -9.73 | |
| Price/FCF | 9.77 | -26.53 | -29.41 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Somewhat Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | inf | 0.00 | 1.01 | |
| Operating Margin | inf | 0.00 | 0.43 | |
| ROA | 37.81 | -0.06 | -0.10 | |
| ROE | -0.12 | -0.07 | 39.64 | |
| ROIC | -0.12 | -0.09 | 28.27 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | -0.03 | -0.03 | -5.35 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | -0.17 | < 0.005 | -98.54 | |
| EPS QOQ | -0.19 | 0.21 | 7.64 | |
| FCF QOQ | -0.13 | -0.15 | -15.07 | |
| Revenue QOQ | -241.76 | 1.00 | -99.59 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | < 0.005 | 0.00 | inf | |
| Days Sales Outstanding (DSO) | -0.80 | 0.00 | inf | |
| Inventory Turnover | 2177000.00 | 0.00 | inf | |
| Debt/Capitalization | 0.05 | 0.03 | -30.41 | |
| Quick Ratio | 13.30 | 11.37 | -14.53 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 7.46 | 9.74 | 30.63 | |
| Cash | 7.48 | 6.27 | -16.20 | |
| Capex | -0.02 | -0.01 | 10.99 | |
| Free Cash Flow | -0.73 | -0.77 | -6.18 | |
| Revenue | -2.21 | 0.00 | inf | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad